168 related articles for article (PubMed ID: 15151944)
1. NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen.
deGraffenried LA; Chandrasekar B; Friedrichs WE; Donzis E; Silva J; Hidalgo M; Freeman JW; Weiss GR
Ann Oncol; 2004 Jun; 15(6):885-90. PubMed ID: 15151944
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
3. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
[TBL] [Abstract][Full Text] [Related]
4. NFκB signaling is important for growth of antiestrogen resistant breast cancer cells.
Yde CW; Emdal KB; Guerra B; Lykkesfeldt AE
Breast Cancer Res Treat; 2012 Aug; 135(1):67-78. PubMed ID: 22527100
[TBL] [Abstract][Full Text] [Related]
5. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
[TBL] [Abstract][Full Text] [Related]
6. Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells.
Jordan NJ; Gee JM; Barrow D; Wakeling AE; Nicholson RI
Breast Cancer Res Treat; 2004 Sep; 87(2):167-80. PubMed ID: 15377841
[TBL] [Abstract][Full Text] [Related]
7. Curcumin induces cell death and restores tamoxifen sensitivity in the antiestrogen-resistant breast cancer cell lines MCF-7/LCC2 and MCF-7/LCC9.
Jiang M; Huang O; Zhang X; Xie Z; Shen A; Liu H; Geng M; Shen K
Molecules; 2013 Jan; 18(1):701-20. PubMed ID: 23299550
[TBL] [Abstract][Full Text] [Related]
8. Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer.
Li D; Ji H; Niu X; Yin L; Wang Y; Gu Y; Wang J; Zhou X; Zhang H; Zhang Q
Cancer Sci; 2020 Jan; 111(1):47-58. PubMed ID: 31710162
[TBL] [Abstract][Full Text] [Related]
9. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis.
Shishodia S; Koul D; Aggarwal BB
J Immunol; 2004 Aug; 173(3):2011-22. PubMed ID: 15265936
[TBL] [Abstract][Full Text] [Related]
10. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells.
Clark AS; West K; Streicher S; Dennis PA
Mol Cancer Ther; 2002 Jul; 1(9):707-17. PubMed ID: 12479367
[TBL] [Abstract][Full Text] [Related]
11. AKT-induced tamoxifen resistance is overturned by RRM2 inhibition.
Shah KN; Mehta KR; Peterson D; Evangelista M; Livesey JC; Faridi JS
Mol Cancer Res; 2014 Mar; 12(3):394-407. PubMed ID: 24362250
[TBL] [Abstract][Full Text] [Related]
12. HMGB1 is a key factor for tamoxifen resistance and has the potential to predict the efficacy of CDK4/6 inhibitors in breast cancer.
Zhang H; Wang J; Li J; Zhou X; Yin L; Wang Y; Gu Y; Niu X; Yang Y; Ji H; Zhang Q
Cancer Sci; 2021 Apr; 112(4):1603-1613. PubMed ID: 33453094
[TBL] [Abstract][Full Text] [Related]
13. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
14. Long Non-Coding RNA (lncRNA) Urothelial Carcinoma-Associated 1 (UCA1) Enhances Tamoxifen Resistance in Breast Cancer Cells via Inhibiting mTOR Signaling Pathway.
Wu C; Luo J
Med Sci Monit; 2016 Oct; 22():3860-3867. PubMed ID: 27765938
[TBL] [Abstract][Full Text] [Related]
15. Akt protects mouse hepatocytes from TNF-alpha- and Fas-mediated apoptosis through NK-kappa B activation.
Hatano E; Brenner DA
Am J Physiol Gastrointest Liver Physiol; 2001 Dec; 281(6):G1357-68. PubMed ID: 11705740
[TBL] [Abstract][Full Text] [Related]
16. Akt-induced tamoxifen resistance is associated with altered FKHR regulation.
Silva J; Cavazos DA; Donzis E; Friedrichs WE; Marciniak R; deGraffenried LA
Cancer Invest; 2007; 25(7):569-73. PubMed ID: 17952739
[TBL] [Abstract][Full Text] [Related]
17. Induction of methionine adenosyltransferase 2A in tamoxifen-resistant breast cancer cells.
Phuong NT; Kim SK; Im JH; Yang JW; Choi MC; Lim SC; Lee KY; Kim YM; Yoon JH; Kang KW
Oncotarget; 2016 Mar; 7(12):13902-16. PubMed ID: 26418898
[TBL] [Abstract][Full Text] [Related]
18. A role of SIPL1/SHARPIN in promoting resistance to hormone therapy in breast cancer.
Ojo D; Wu Y; Bane A; Tang D
Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):735-745. PubMed ID: 29248549
[TBL] [Abstract][Full Text] [Related]
19. Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth.
Frogne T; Jepsen JS; Larsen SS; Fog CK; Brockdorff BL; Lykkesfeldt AE
Endocr Relat Cancer; 2005 Sep; 12(3):599-614. PubMed ID: 16172194
[TBL] [Abstract][Full Text] [Related]
20. AKT activation predicts outcome in breast cancer patients treated with tamoxifen.
Kirkegaard T; Witton CJ; McGlynn LM; Tovey SM; Dunne B; Lyon A; Bartlett JM
J Pathol; 2005 Oct; 207(2):139-46. PubMed ID: 16088978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
